Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
editorial
. 1998 Nov;42(11):3051–3052. doi: 10.1128/aac.42.11.3051

Novel Combination of Mutations in the DNA Gyrase and Topoisomerase IV Genes in Laboratory-Grown Fluoroquinolone-Resistant Shigella flexneri Mutants

Yiu-Wai Chu 1, Elizabeth T S Houang 1, Augustine F B Cheng 1
PMCID: PMC105997  PMID: 9867794

A ciprofloxacin-susceptible strain (wild type [WT]) of Shigella flexneri (MIC, 0.015 μg/ml), isolated from a stool sample in 1996 was passaged (about 1010 cells) onto ciprofloxacin-containing (0.5 to 32 μg/ml) Isosensitest medium (Oxoid) to obtain single colonies after 36-h incubation. Two resistant mutants (A and B) were thus obtained. Table 1 shows MICs of nine antimicrobial agents, determined by the agar dilution method (14).

TABLE 1.

Mutations in the gyrA and parC QRDR in the WT and mutants A and B and MICs of nine antimicrobial agents

Strain MIC (μg/ml)a
gyrA codon 87 parC
CIP NAL NOR GEN TOB ACR TET CHL IMP Codon 79 Codon 84
WT 0.015 1 0.12 0.5 0.25 16 128 64 0.25 GAC (Asp) GAT (Asp) GAA (Glu)
A 16 >1,024 32 0.5 1 32 512 512 0.25 TAC (Tyr) GCT (Ala) GAA (Glu)
B 64 >1,024 64 0.5 1 64 512 512 0.12 TAC (Tyr) GCT (Ala) GCA (Ala)
a

CIP, ciprofloxacin; NAL, nalidixic acid; NOR, norfloxacin; GEN, gentamicin; TOB, tobramycin; ACR, acriflavin; TET, tetracycline; CHL, chloramphenicol; IMP, impenem. 

The quinolone resistance determining regions (QRDR) of gyrA (648 bp), gyrB (184 bp), parC (531 bp), and parE (265 bp) for WT and its two mutants were amplified with the following primer pairs: 5′-TACACCGGTCAACATTGAGG-3′ and 5′-TTAATGATTGCCGCCGTCGG-3′, 5′-CAGACTGCCAGGAACGCGAT-3′ and 5′-AGCCAAGTGCGGTGATAAGA-3′, 5′-GTACGTGATCATGGACCGTG-3′ and 5′-TTCGGCTGGTCGATTAATGC-3′, and 5′-TACCGAGCTGTTCCTTGTGG-3′ and 5′-GGCAATGTGCAGACCATCAG-3′. Single-strand conformational polymorphism analysis was applied to all PCR products (CleanGel S48 kit; Pharmacia) and revealed mutations in the QRDR of gyrA and parC, but not gyrB and parE, in mutants A and B. Cycle sequencing subsequently identified these mutations with the nested primers 5′-ACGCCAGACAACCGTTGA-3′ and 5′-ATGCGGTGGAATATCGGTCG-3′ for gyrA and parC, respectively. Changes in amino acids at the mutation sites are shown in Table 1.

The genetic basis of resistance to quinolones in gram-negative bacteria has been defined mainly in Escherichia coli. Substitution of the highly conserved residue Ser-83 in GyrA is the most common alteration in both in vivo- and in vitro-resistant isolates (5, 15). The mutation altering the residue Asp-87 is usually found to augment the Ser-83 mutation for further resistance increase (5, 12). Replacement of the residues Ser-80 and Glu-84 in ParC is commonly associated with the gyrA mutations to procure high fluoroquinolone resistance (6, 8, 13). Mutations in the QRDR of gyrB and parE of E. coli appear to be uncommon (2). Mutation in the codon for Ser-83 has been reported to be present in isolates of Shigella dysenteriae and S. flexneri resistant to nalidixic acid (1, 11). We report here the association of ciprofloxacin resistance with a novel combination of alterations at Asp-87 (to Tyr) in GyrA and Asp-79 (to Ala) in ParC in two laboratory-grown mutants. Higher resistance was associated with an additional mutation at Glu-84 (to Ala) in ParC in mutant B. Although the amino acid changes in GyrA and ParC identified have not been proven to cause the resistance phenotype, these findings suggest that they may be associated with the development of higher-level fluoroquinolone resistance. A single alteration at Asp-87 (to Tyr) or its homologs in gram-negative bacteria is uncommon and only found in isolates with low level of resistance, e.g., Serratia marcescens (7), Haemophilus influenzae (3), Citrobacter freundii (9), and Salmonella (4). Construction of hybrid plasmids and transformation demonstrated that changes at Asp-87 alone led to an increase in the ciprofloxacin MIC from 0.02 to 0.16 mg/ml for E. coli (10). Alteration at Asp-79 (to Ala) in ParC has so far not been reported in association with fluoroquinolone resistance. The increases in MICs of tetracycline, tobramycin, chloramphenicol, and acriflavin suggest that another resistance mechanism(s) may also be involved, such as Mar as described for Pseudomonas aeruginosa after serial exposure to fluoroquinolones (16).

Nucleotide sequence accession numbers.

The partial sequence data of the S. flexneri gyrA and parC genes reported here appear in the GenBank database under the accession no. AF065131 and AF065132, respectively.

Acknowledgments

This project was supported by a grant from Hong Kong University Research Grants Council (no. 2040496).

REFERENCES

  • 1.Chu Y W, Houang E T S, Lyon D J, Ling J M, Ng T K, Cheng A F B. Antimicrobial resistance in Shigella flexneri and Shigella sonnei in Hong Kong, 1986 to 1995. Antimicrob Agents Chemother. 1997;42:440–443. doi: 10.1128/aac.42.2.440. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Everett M J, Jin Y F, Ricci V, Piddock L J V. Contributions of individual mechanisms to fluoroquinolone resistance in 36 Escherichia coli strains isolated from humans and animals. Antimicrob Agents Chemother. 1996;40:2380–2386. doi: 10.1128/aac.40.10.2380. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Georgiou M, Munoz R, Roman F, Canton R, Gomez-Lus R, Campos J, de la Campa A G. Ciprofloxacin-resistant Haemophilus influenzae strains possess mutations in analogous positions of gyrA and parC. Antimicrob Agents Chemother. 1996;40:1741–1744. doi: 10.1128/aac.40.7.1741. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Griggs D J, Gensberg K, Piddock L J V. Mutations in gyrA gene of quinolone-resistant Salmonella serotypes isolated from humans and animals. Antimicrob Agents Chemother. 1996;40:1009–1013. doi: 10.1128/aac.40.4.1009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Heisig P, Tschorny R. Characterisation of fluoroquinolone-resistant mutants of Escherichia coli selected in vitro. Antimicrob Agents Chemother. 1994;38:1284–1291. doi: 10.1128/aac.38.6.1284. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Heisig P. Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli. Antimicrob Agents Chemother. 1996;40:879–885. doi: 10.1128/aac.40.4.879. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Kim J H, Cho E H, Kim K S, Kim H Y, Kim Y M. Cloning and nucleotide sequence of the DNA gyrase gyrA gene from Serratia marcescens and characterization of mutations in gyrA of quinolone-resistant clinical isolates. Antimicrob Agents Chemother. 1998;42:190–193. doi: 10.1128/aac.42.1.190. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Kumagai Y, Kato J, Hoshino K, Akasaka T, Sato K, Ikeda H. Quinolone-resistant mutants of Escherichia coli DNA topoisomerase IV parC gene. Antimicrob Agents Chemother. 1996;40:710–714. doi: 10.1128/aac.40.3.710. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Nishino Y, Deguchi T, Yasuda M, Kawamura T, Nakano M, Kanematsu E, Ozeki S, Kawada Y. Mutations in the gyrA and parC genes associated with fluoroquinolone resistance in clinical isolates of Citrobacter freundii. FEMS Microbiol Lett. 1997;154:409–414. doi: 10.1111/j.1574-6968.1997.tb12675.x. [DOI] [PubMed] [Google Scholar]
  • 10.Ouabdesselam S, Hooper D C, Tankovic J, Soussy C J. Detection of gyrA and gyrB mutations in quinolone-resistant clinical isolates of Escherichia coli by single strand conformational polymorphism analysis and determination of levels of resistance conferred by two different single gyrA mutations. Antimicrob Agents Chemother. 1995;9:1667–1670. doi: 10.1128/aac.39.8.1667. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Rahman M, Mauff G, Levy J, Couturier M, Pulverer G, Glasdorff N, Butzler J P. Detection of 4-quinolone resistance mutation in gyrA gene of Shigella dysenteriae type 1 by PCR. Antimicrob Agents Chemother. 1994;38:2488–2491. doi: 10.1128/aac.38.10.2488. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Vila J, Ruiz J, Marco F, Balcelo A, Goñi P, Giralt E, Jimenez De Anta T. Association between double mutation in gyrA gene of ciprofloxacin-resistant clinical isolates of Escherichia coli and MICs. Antimicrob Agents Chemother. 1994;38:2477–2479. doi: 10.1128/aac.38.10.2477. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Vila J, Ruiz J, Goni P, De Anta T J. Detection of mutations in parC in quinolone-resistant clinical isolates of Escherichia coli. Antimicrob Agents Chemother. 1996;40:491–493. doi: 10.1128/aac.40.2.491. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Working Party Report of the British Society for Antimicrobial Chemotherapy. 1991. A guide to sensitivity test. J. Antimicrob. Chemother. 27(Suppl. D):22–30. [PubMed]
  • 15.Yoshida H, Bogaki M, Nakamura M, Nakamura S. Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob Agents Chemother. 1990;34:1271–1272. doi: 10.1128/aac.34.6.1271. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Zhanel G G, Karlowsky J A, Saunders M H, Davidson R J, Hoban D J, Hancock R E W, McLean I, Nicolle L E. Development of multiple-antibiotic-resistance (Mar) mutants of Pseudomonas aeruginosa after serial exposure to fluoroquinolones. Antimicrob Agents Chemother. 1995;39:489–495. doi: 10.1128/aac.39.2.489. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES